Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data

被引：0

作者：

Melendres-Groves, Lana ^{[1
]}

Channick, Richard ^{[2
]}

Chin, Kelly ^{[3
]}

Mclaughlin, Vallerie V. ^{[4
]}

Flynn, Megan ^{[5
]}

Ong, Rose ^{[6
]}

Wetherill, Graham ^{[6
]}

Kim, Nick H. ^{[7
]}

机构：

[1] Univ New Mexico, Albuquerque, NM 87131 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] UT Southwestern Med Ctr, Dallas, TX USA

[4] Univ Michigan, Ann Arbor, MI 48109 USA

[5] Actelion Pharmaceut US Inc, San Francisco, CA USA

[6] Actelion Pharmaceut Ltd, Allschwil, Switzerland

[7] Univ Calif San Diego, La Jolla, CA 92093 USA

来源：

EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷

关键词：

Chronic diseases; Treatments; Pulmonary hypertension;

D O I：

10.1183/13993003.congress-2020.1463

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

1463

引用

页数：2

共 50 条

[41] Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Real-World Experience with Macitentan
Channick, R.
McLaughlin, V.
Chin, K.
McConnell, J.
Poch, D.
Brand, M.
Selej, M.
Morganti, A.
Kim, N.
[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S483 - S483
[42] SAFETY OF MACITENTAN IN PORTOPULMONARY HYPERTENSION (POPH): REAL-WORLD EXPERIENCE BY LIVER TRANSPLANT CANDIDACY IN THE OPUS REGISTRY
DuBrock, Hilary Megan
Channick, Richard
Kim, Nick H.
McLaughlin, Vallerie
Agron, Peter
Leroy, Sandrine
Wetherill, Graham
Chin, Kelly
[J]. HEPATOLOGY, 2020, 72 : 1081 - 1081
[43] OPUS Registry: Treatment Patterns and Safety of Macitentan in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (PAH-SSc)
Chin, Kelly
Kim, Nick
Channick, Richard
Rouzic, Erwan Muros-Le
Selej, Mona
McLaughlin, Vallerie
[J]. CHEST, 2017, 152 (04) : 999A - 1000A
[44] Real-World Treatment Patterns in Hispanic and White Patients With Pulmonary Arterial Hypertension (PAH) in the United States
Melendres-Groves, Lana
Tang, Wenze
Germack, Hayley D.
Liu, Zhiwen
Sadik, Kay
[J]. CIRCULATION, 2023, 148
[45] REAL-WORLD USE OF SELEXIPAG AND OTHER PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPIES: AN OBSERVATIONAL COHORT STUDY IN PATIENTS WITH PAH (EXPOSURE)
Muller, A.
Soderberg, S.
Escribano, P.
Biedermann, P.
Sun, H.
Lange, T. J.
Gaine, S.
[J]. VALUE IN HEALTH, 2019, 22 : S602 - S603
[46] Persistence with macitentan versus other endothelin receptor antagonists in patients with pulmonary arterial hypertension: experience from a real-world data repository in the USA
Worden, C.
Azam, S.
Kouhkamari, M.
Caillet, V.
Panjabi, S.
[J]. EUROPEAN HEART JOURNAL, 2022, 43 : 2194 - 2194
[47] Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy
Simonneau, Gerald
Channick, Richard
Delcroix, Marion
Galie, Nazzareno
Ghofrani, Hossein
Jansa, Pavel
Le Brun, Franck-Olivier
Mehta, Sanjay
Perchenet, Loic
Pulido, Tomas
Sastry, B.
Sitbon, Olivier
Souza, Rogerio
Torbicki, Adam
Rubin, Lewis
[J]. CHEST, 2013, 144 (04)
[48] Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
Hamilton, Neil
Sellars, Michaela
Graves, Mark
Armstrong, Iain
Charalampopolous, Athanasios
Kiely, David
Elliot, Charlie
Condliffe, Robin
[J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[49] A RETROSPECTIVE DATABASE STUDY TO EVALUATE THE ECONOMIC BURDEN FOR INCIDENT AND PREVALENT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) IN ENGLAND
Beaudet, A.
Yesufu-Udechuku, A.
Davies, E. W.
Taylor, L. H.
Sikander-Rehman, S.
Ogley, R.
Hermans, R.
Nordgren, A.
Exposto, F.
[J]. VALUE IN HEALTH, 2019, 22 : S350 - S351
[50] Real-World Evidence from the OPUS Registry: An Insight into Pulmonary Arterial Hypertension Risk Assessment Parameters in Clinical Practice
Chin, K. M.
Channick, R. N.
Kim, N. H.
Brand, M.
Morganti, A.
Selej, M.
McLaughlin, V. V.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199

← 1 2 3 4 5 →